Glutamate related metabolism in animal models of schizophrenia
Year: 2011
Type: dissertation
Abstract: Schizophrenia is a clinical syndrome of variable psychopathology, which involves thought, perception, emotion, movement and behavior. The cumulative effect of the illness is always severe and usually long lasting. Epidemiologic studies indicate that the lifetime expectancy is 0.5-1% worldwide. The etiology and pathophysiology of schizophrenia are unknown. The two predominant pathophysiological hypotheses of schizophrenia are the dopamine hypothesis and the glutamate hypothesis. The former hypothesis states that dopamine neurotransmission is hyperactive in schizophrenia, the latter – that there is a hypofunction of glutamatergic neurotransmission in some areas of the brain. Recent studies also suggest that schizophrenia is associated with cytoskeletal alterations in neuronal architecture, e.g. differences in micro tubule associated proteins (MAP). The symptoms of schizophrenia are mostly unique to human behavior. Consequently, the exact reproduction of schizophrenia in an animal is not possible. However, animal models are important tools for exploring the underlying mechanisms of schizophrenia and for designing new therapies. The present thesis is based on four publications on animal models of schizophrenia. We used the NMDA receptor antagonist MK-801 to induce a state of hypoglutamatergia in rats in the three of them. Three different designs were used: injection of a single high dose, repeated high dose injections over several days and repeated injections of a lower dose. The fourth study was designed to investigate glutamate related metabolism in a state of microtubule instability. Knock out mice were used as a model, in which the gene coding for the microtubule associated protein STOP (Stable Tubule Only Peptide) was deleted. Glutamate related metabolism was investigated in these models by analyzing brain extracts from multiple brain areas, using HPLC (High Performance Liquid Chromatography) and 13C and1H nuclear magnetic resonance spectroscopy. By injecting animals with 1-13C labeled glucose and 1,2-13C labeled acetate, the preferential substrates of neurons and astrocytes, respectively, it was possible to follow metabolic interactions between astrocytes and neurons. A single dose of 0.5 mg/kg MK-801 produced predominantly changes in the temporal lobe with increased total amounts of glutamate and glutamine, and increased labeling from [1-13C]glucose. Similar changes were observed when MK-801 was administered repeatedly at 0.1 mg/kg for 6 consecutive days and all the metabolic alterations were confined to the temporal lobe. However, while 0.5 mg/kg MK-801 was used repeatedly instead of 0.1 mg/kg MK-801, changes were found in the cingulate, retrosplenial and frontal cortices. The total amount of glutamate increased in those areas together with a decrease in labeling from both [1-13C]glucose and [1,2-13C]acetate in several metabolites. In Paper 4 decreased levels of both total glutamine and labeled [4,5-13C]glutamine were reported in the cerebrum of STOP knock out mice. Compared to data from studies of schizophrenic patients, our results indicate that repeated injections of MK-801 in high doses may be a good model for first episode schizophrenia and the STOP KO mouse model show similarities to and may be a good model chronic schizophrenia. Results show that both the NMDA receptor hypofunction and the loss of microtubule stability seem to disrupt the glutamate-glutamine cycle, and it can be stated that astrocytic-neuronal interactions probably are underestimated in schizophrenia research.
Source: NVA (Nasjonalt vitenarkiv)
Author: Eiliv Brenner
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W155036640
